H. EngelholmThomas H. Bugge, Niels Behrendt and LarsA Madsen, Peter Garred, Sven Burgdorf, Amanda Moyer, Christian Honore, CharlotteJurgensen, Maria C. Melander, Lars Kjoller, Daniel H. Madsen, Signe Ingvarsen, Henrik J.  uptake: a distinct degradation pathwayThe non-phagocytic route for collagenRegular Paper:

published online June 7, 2011J. Biol. Chem. 

  10.1074/jbc.M110.208033Access the most updated version of this article at doi:

  .JBC Affinity SitesFind articles, minireviews, Reflections and Classics on similar topics on the

 Alerts:

  When a correction for this article is posted• 

When this article is cited• 

to choose from all of JBC's e-mail alertsClick here

Supplemental material:

  http://www.jbc.org/content/suppl/2011/06/06/M110.208033.DC1.html

  http://www.jbc.org/content/early/2011/06/06/jbc.M110.208033.full.html#ref-list-1

This article cites 0 references, 0 of which can be accessed free at

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

by guest on D

ecember 5, 2013

http://ww

w.jbc.org/

Dow

nloaded from

1

THE NON-PHAGOCYTIC ROUTE OF COLLAGEN UPTAKE: A DISTINCT DEGRADATION PATHWAY

Daniel H. Madsen1, Signe Ingvarsen1,2, Henrik J. Jürgensen1, Maria C. Melander1, Lars Kjøller1,6,

Amanda Moyer3, Christian Honoré4, Charlotte A. Madsen1, Peter Garred4, Sven Burgdorf5, Thomas H. Bugge3, Niels Behrendt1, Lars H. Engelholm1

From the Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark1, the Department of Biology, University of Copenhagen, Copenhagen, Denmark2, Oral and Pharyngeal Cancer Branch, National Institute of Dental

and Craniofacial Research, National Institutes of Health, Bethesda, MD3, Laboratory of Molecular Medicine, Department of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark4 and Life and Medical Science

(LIMES) Institute, University of Bonn, Germany5. 6Present address: LEO Pharma, Ballerup, Denmark

Corresponding author: Lars H. Engelholm, The Finsen Laboratory, Rigshospitalet, Copenhagen Biocenter, Ole Maaloes Vej 5, DK-2200, Copenhagen, Denmark. Tel: +45 3545 6045. Fax: +45 3545 3797. E-mail: lhe@finsenlab.dk The degradation of collagens, the most abundant proteins of the extracellular matrix, is involved in numerous physiological and pathological conditions including cancer invasion. An important turnover pathway involves the cellular internalization and degradation of large, soluble collagen fragments, generated by initial cleavage of insoluble collagen fibers. We have previously observed that in primary mouse fibroblasts, this endocytosis of collagen fragments is dependent on the receptor urokinase plasminogen activator receptor-associated protein (uPARAP)/Endo180. Others have identified additional mechanisms of collagen uptake, with different associated receptors, in other cell types. These receptors include beta1-integrins, being responsible for collagen phagocytosis, and the mannose receptor. We have now utilized a newly developed monoclonal antibody against uPARAP/Endo180, which downregulates the receptor protein level on treated cells, to examine the role of uPARAP/Endo180 as a mediator of collagen internalization by a wide range of cultured cell types. With the exception of macrophages, all cells that proved capable of efficient collagen internalization were of mesenchymal origin and all of these utilized uPARAP/Endo180 for their collagen uptake process. Macrophages internalized collagen in a process mediated by the mannose receptor, a protein belonging to the same protein family as uPARAP/Endo180. Beta1-integrins were found not to be involved in the endocytosis of soluble collagen, irrespectively of whether this was mediated by uPARAP/Endo180 or the mannose receptor. This

further distinguishes these pathways from the phagocytic uptake of particulate collagen. Remodeling of the extracellular matrix (ECM) is required for a wide range of physiological and pathological conditions such as morphogenesis, organ growth, wound healing, arthritis, fibrosis and tumor growth and metastasis (1-4). Collagens are the most abundant components of the ECM with collagen type I as the quantitatively dominating subtype. Thus, collagen constitutes about 25-30% of the dry weight of a human (5). The collagen in the body is undergoing continuous renewal and normally the collagen turnover rate is carefully controlled. Depending on the tissue type or extraneous events the collagen turnover rate can change dramatically. Therefore, highly efficient biological systems are needed in both the formation and degradation of collagen throughout life. In normal healthy tissue, collagen is fully hydroxylated and forms insoluble, cross-linked fibers and sheets of triple helical structures that are resistant to attack by most proteases (6). A number of proteases are nevertheless potentially capable of initiating the collagen degradation process through the cleavage of intact collagen fibers. These proteases are the matrix metalloproteinases (MMPs) MMP-1, MMP-2, MMP-8, MMP-13, MMP-14, MMP-15 and MMP-16 and the cysteine protease cathepsin K (7-9). So far, most studies of collagen turnover have focused on the extracellular collagen degradation mediated solely by these proteases. Recently, however, we have established an important interplay between the extracellular collagenases and a collagen degradation pathway

http://www.jbc.org/cgi/doi/10.1074/jbc.M110.208033The latest version is at JBC Papers in Press. Published on June 7, 2011 as Manuscript M110.208033

Copyright 2011 by The American Society for Biochemistry and Molecular Biology, Inc.

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

2

that involves endocytic uptake and intracellular degradation of well-defined collagen fragments. In particular, we have demonstrated that the collagen fragments generated through the initial MMP-mediated cleavage of collagen fibers can be efficiently endocytosed and degraded in the lysosomes in a process mediated by the specific endocytic receptor, the urokinase plasminogen activator receptor associated protein (uPARAP)/Endo180. This sequential degradation mechanism is required for complete and efficient collagen turnover by mouse skin fibroblasts (10,11). We have also demonstrated that the uptake of solubilized, intact collagen mimics the efficient uptake of the defined MMP-generated collagen fragments (11). In addition to this composite collagen degradation pathway involving non-phagocytic collagen internalization, an alternative collagen uptake mechanism also exists. This latter pathway is dependent on beta1-integrin activity and concerns the phagocytic uptake of large collagen particles (12-14). At present, the elucidation of the exact role of the different collagen receptors is an important issue. Through the generation of uPARAP/Endo180 knockout mice, we have previously demonstrated that uPARAP/Endo180 is an indispensable component for the internalization and lysosomal degradation of solubilized collagen by primary mouse fibroblasts, chondrocytes, and osteoblasts (10,15,16). The uptake mechanism of uPARAP/Endo180 has been shown to function through constitutively recycling, clathrin-mediated endocytosis (17,18). Even though phenotypic studies of unchallenged uPARAP/Endo180 knockout mice have only revealed rather modest phenotypic consequences ((16) and Madsen et al., unpublished), lack of uPARAP/Endo180 can lead to a dramatic collagen accumulation in pathological conditions with high collagen turnover such as cancer (19), thereby confirming a role of uPARAP/Endo180 in the process of ECM turnover in vivo. This role of uPARAP/Endo180 was further substantiated by the recent identification of a uPARAP/Endo180 null mutation in cattle, which leads to a severe syndrome characterized by dramatic bone defects (20). These studies demonstrate the importance of the uPARAP/Endo180-dependent collagen degradation pathway in vivo and illuminate the need for further investigations of this mechanism.

uPARAP/Endo180 is expressed in a variety of different tissues (21,22) but a high uPARAP/Endo180 expression is in particular observed at sites of tissue remodeling, such as in the osteoblasts and chondrocytes of the developing bones (16,23,24). uPARAP/Endo180 is frequently upregulated in invasive cancers (25-29), and most often expression is observed in the stromal cells. However, the total spectrum of cell types expressing uPARAP/Endo180 is not yet known and it is also unclear whether in all cases the receptor is active in and required for collagen turnover (30). In this paper, we describe an investigation of the uptake of solubilized collagen in several cell types of human and murine origin. By preventing collagen uptake with a highly efficient mAb against uPARAP/Endo180 and using cells with deficiency for this and other collagen receptors, we can now define the non-phagocytic pathway of collagen degradation as a distinct mechanism in molecular terms. Depending on the cell type, this pathway is governed by either uPARAP/Endo180 or by another member of the same protein family, the mannose receptor.

Experimental Procedures

Reagents- The monoclonal mouse anti-uPARAP/Endo180 antibodies (mAbs) 5f4 and 2h9F12 were raised against purified recombinant soluble uPARAP/Endo180 and produced as previously described (28). Isotype-matched control anti-TNP antibody was produced as described in (31). The following proteins were purchased from the commercial sources indicated: acid-extracted collagen type I from rat tail collagen, monoclonal antibody against murine beta1-integrin (clone HA2/5) and PE-conjugated anti-CD206 antibody (BD Biosciences, Franklin Lanes, NJ), Oregon Green labeled gelatin, Oregon Green labeled collagen type IV, holo-transferrin and cysteine protease inhibitor E64d (Calbiochem, San Diego, CA), interleukin 1β and tumor necrosis factor-α (Peprotech, Rocky Hill, NJ), iodine-125 (Perkin Elmer, Waltham, MA), monoclonal antibody against human beta1-integrin (clone 4B4) (Beckman Coulter, Brea, CA), cyclic RGD-peptide (Peptides International, Louisville, KT), mannose-BSA (Dextra Laboratories, Reading, United Kingdom), CellMask Orange (Invitrogen, Carlsbad, CA, USA), granulocyte macrophage colony-stimulating-factor (GM-CSF) (Sigma-Aldrich, St. Louis, MO), FITC-

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

3

conjugated anti-mouse antibody (DAKO, Glostrup, Denmark) and proteinase K (Roche, Basel, Switzerland). Cultured cells- For the generation of human macrophages, monocytes were isolated from human blood as described (32). The monocytes were seeded in the wells of a 24-well cell culture plate and differentiated into macrophages using granulocyte macrophage colony-stimulating-factor (GM-CSF) at a concentration of 5 ng/ml over a 7-day span. The cells were cultured in AIM-V supplemented with 10% FCS and medium was replenished on day 4. Animal experiments were approved the NIDCR Animal Care and Use Committee. For the isolation of activated murine macrophages, wildtype and littermate mannose receptor-/- mice in C57BL/6J background (33) were injected intraperitoneally with 2 ml of a 2 % Brewers TG solution (BD Biosciences, Franklin Lanes, NJ). Mice were killed after 72 hours and peritoneal cells were collected by lavage using 10 ml cold PBS. The lavage fluid was centrifuged, the supernatant aspirated, and the cell pellet resuspended in complete RPMI 1640 medium with 10% DMSO, and the cells were frozen for later use. Cells were then frozen directly for later use. After thawing, cells were seeded in the wells of a 24-well cell culture plate in RPMI with 10% FCS and 1% penicillin/streptomycin, and the adherent cells were used for analysis. The following established cell lines were purchased from the indicated sources or from sources described previously: Human gingival fibroblast cell line HGF-1 (ATCC number CRL-2014), murine sarcoma cell line NCTC 2472 (ATCC number CCL-11), human osteosarcoma cell line MG63 (ATCC number CRL-1427), murine fibroblast cell line NIH/3T3 (ATCC number CRL-1658), human prostate carcinoma cell line LNCaP (ATCC number CRL-1740), human lung fibroblast cell line MRC-5 (ATCC number CCL-171), murine melanoma cell line B16F10 (ATCC number CRL-6475) and human colorectal adenocarcinoma cell line CaCo-2 (ATCC number HTB-37) were all purchased from American Type Culture Collection, ATCC, Manassas, VA. Human fibrosarcoma cell line HT1080, human rhabdomyosarcoma cell line RD and the human cervix carcinoma cell line HeLa (34), human breast adenocarcinoma cell line MCF-7 (35), human embryonic kidney cell line HEK-293 (36), murine Lewis Lung Carcinoma (LLC) (37), human breast adenocarcinoma cell line MDA-MB-

231 (38). All cell lines were cultured according to ATCC guidelines. Murine beta1-integrin deficient fibroblasts (GD25) and GD25 fibroblasts re-transfected with beta1-integrin (GD25-beta) were kind gifts from Reinhard Fässler (39). Primary skin fibroblasts were isolated from newborn uPARAP/Endo180-/- or littermate wildtype (uPARAP/Endo180+/+) mice as previously described (15). Fibroblasts were cultured in DMEM with 10% FCS and 1% penicillin/streptomycin. Cell and organ extracts and Western blotting- Cultured MG-63 cells and fibroblasts from uPARAP/Endo180+/+ or littermate uPARAP/Endo180-/- mice were lysed in a Triton X-100 lysis buffer (10 mM Tris-HCl, 140 mM NaCl, pH 7.4, 1 % Triton X-100, including protease inhibitor cocktail III (Calbiochem)). Hearts and lungs were isolated from uPARAP+/+ mice or littermate uPARAP-/- mice after perfusion of the mice with 10 ml PBS. The organs were ground in liquid nitrogen using a mortar and pestle and homogenized in a CHAPS lysis buffer (0.1 M Tris-HCl, 50 mM NaCl, pH 7.5, 2 % CHAPS, protease inhibitor cocktail III) using a polytron homogenizer. The cell lysates and organ homogenates were clarified by centrifugation at 20,000 x g for 15 min. at 4°C. Protein concentrations were determined using a BCA assay (Pierce) according to the manufacturer’s instructions. SDS-PAGE was performed with 15 µg of cell lysate or organ homogenate loaded in each well followed by electroblotting onto PVDF membranes. For the analysis of mAb 5f4 specificity, Western blotting was performed with fibroblast lysates as previously described (15) using mAb 5f4 at a final concentration of 2 µg/ml. For the analysis of organ homogenates the PVDF membrane was incubated with 20 ng/ml of 125I-labeled mAb 5f4 at 4°C overnight followed by automated phosphorimager analysis as previously described (11). Band intensities were quantified using the Image Gauge software (Fujifilm, Tokyo, Japan). Endocytosis studies- Labeling of proteins with 125I and internalization studies of radiolabeled ligands by cultured cells was performed essentially as described in (15). All cells, except for macrophages, were seeded in 24-well tissue culture plates at a density of 1*105 cells/well. Macrophages were seeded at a density of 2*105 cells/well. Cells were cultured overnight to ensure maximal surface adherence. For the functional blocking of

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

4

uPARAP/Endo180 the monoclonal antibody (mAb) 5f4 was added to a concentration of 10 µg/ml (unless another concentration is indicated) during this cell culture period. Isotype-matched control antibody, anti-TNP, was likewise added during this period. The cells were subsequently washed gently in serum-free cell culture medium at 37°C and were then pre-incubated for 30 min. in assay buffer (the appropriate cell culture medium with 20 mM Hepes, pH 7.4 and 15 mg/ml BSA). In experiments with functional blocking of uPARAP/Endo180, this preincubation buffer included mAb 5f4 or negative control antibody (anti-TNP) at a concentration of 10 µg/ml (unless another concentration is indicated). In experiments, which included functional blocking of integrins, the preincubation buffer included 2 µg/ml or 10 µg/ml of the indicated antibody or the indicated concentration of cyclic RGD peptide. A relatively short pre-incubation period in the presence of integrin-blocking reagents (30 min, without preceding overnight culture) proved necessary in order to prevent detachment of the cells (results not shown). In separate experiments, it was ascertained that a similar short preincubation procedure with 5f4 antibody (omitting the overnight pre-culture with antibody) did not influence the blocking efficiency markedly compared to experiments with overnight preincubation (data not shown). The assay buffer was removed and replaced by assay buffer containing 133 ng/ml 125I-labeled protein and the indicated blocking reagents, followed by incubation at 37°C. The cells were allowed to internalize ligand for 4-5 hours and then washed three times with ice-cold PBS, and incubated for <5 min in Trypsin-EDTA with 50 µg/ml proteinase K to remove surface-bound material. The detached cells were centrifuged at 1,000 g for 1 min at 4°C, and the radioactivity in the pellet (internalized material) and supernatant (surface-released material) was measured in a gamma counter. In each analysis, a maximum of 4 cell lines were examined and to minimize assay to assay variations, MG63 cells were always included as a reference cell line and measured values were normalized to those of MG63. For each cell line the collagen internalization was measured multiple times. For the determination of the cellular protein level of uPARAP/Endo180, the cells were incubated with radiolabeled anti-uPARAP/Endo180 mAb 2h9F12 for 4 hours and the total amount of cell-associated mAb 2h9F12 was measured. Incubation of cultured cells with Oregon Green

labeled gelatin or collagen type IV followed by fluorescence microscopy with a Zeiss LSM 510 microscope was performed as described previously for fluorescence-labeled collagen type IV (10), using an incubation period of 18-20 h in the absence of protease-inhibitor or in the presence of 20 µM E64d. The cell surface of the murine fibroblasts was stained as described in (10) using a monoclonal antibody against uPAR and the cell surface of MG63 cells was stained with 1 µg/ml CellMask Orange for 5 min before fixation of the cells. Effect of antibody on uPARAP/Endo180 protein level- Wildtype mouse primary skin fibroblasts or human MG63 cells were seeded in 6-well plates at a density of 6*105 cells per well. Cells were cultured overnight at 37°C, after which mAb 5f4 (10 µg/ml) was added. Control samples were cultured in the presence of 10 µg/ml isotype-matched control antibody (anti-TNP). After 24 h, cells were washed briefly in the wells with PBS with 5 mM EDTA, followed by addition of a fresh aliquot (2 ml) of the same buffer. After incubation for 30 min. at 37°C, cells were detached by pipetting in the same aliquot of incubation buffer and transferred to Eppendorf-tubes. The tubes were then centrifuged for 5 min at 400 x g. 80 µl lysis buffer (10 mM Tris-HCl, 140 mM NaCl, pH 7.4 with 1 % Triton X-100 and protease-inhibitor cocktail III) was added to each cell pellet, followed by resuspension of cells. Tubes were then placed on ice for 20 min, vortexed and centrifuged for 20 min at 4°C, 13,000 x g, after which the supernatant was transferred to new tubes. Protein concentrations were determined using a BCA assay and equal protein amounts from each sample of the supernatants were analyzed by Western blotting using 125I-labeled anti-uPARAP/Endo180 antibody as described above, except that mAb 2h9F12 was used. SDS-PAGE analysis and Coomassie-staining was included to ensure that equal protein amounts were indeed loaded. Collagen degradation assay- A collagen matrix was reconstituted by polymerization and drying of acid-extracted collagen type I as described in (40) with inclusion of trace amounts of radiolabeled collagen type I as described in (11). Fibroblasts were cultured on the collagen-matrix in DMEM including 1 nM interleukin 1β and 10 nM tumor necrosis factor-α in the absence of mAb 5f4 or in the presence of 50 µg/ml mAb 5f4. After 5 days, the conditioned media

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

5

was collected and analyzed by SDS-PAGE followed by automated phosphorimager analysis. For the generation of collagen fragments collagen type I was cleaved with recombinant MMP-13 as previously described (11). Flow cytometry analysis of uPARAP/Endo180 and mannose receptor expression- Dissociated cells were washed twice in PBS-buffer with 5% FCS, and incubated for 30 min, 4°C in 5 ug/ml unlabeled primary antibody or in 0.625 µg/ml PE-conjugated CD206 antibody. The cells were washed in PBS-buffer containing 5% FCS and in the case of CD206 analyzed directly on a FACScalibur flow cytometer (BD Biosciences, Franklin Lanes, NJ). For the analysis of uPARAP/Endo180 expression, cells were washed as above and incubated for 30, 4°C in a 1:100 dilution of secondary FITC-conjugated anti-mouse antibody. Cells were subsequently washed in PBS-buffer + 5% FCS and analyzed by flow cytometry.

RESULTS

Blocking collagen uptake through uPARAP/Endo180. To enable the specific inhibition of the uPARAP/Endo180-dependent collagen uptake mechanism, a panel of monoclonal antibodies (mAbs) was generated by immunization of uPARAP/Endo180-deficient (-/-) mice with recombinant human uPARAP/Endo180. The utilization of mice with a deletion of the gene of interest allows for the generation of mAbs capable of recognizing human uPARAP/Endo180 as well as the interspecies conserved parts of the protein (41-43). We successfully generated eight mAbs against human uPARAP/Endo180, of which seven cross-reacted with the murine protein (results not shown). The specificity of one of these antibodies, designated 5f4, is shown in Fig. 1A. Both in cultured fibroblasts (left panel) and mouse organ extracts such as heart and lung (right panel), the antibody displayed a very high specificity since only one protein band was detected, migrating with an apparent Mr of 180 kDa. This protein was indeed uPARAP/Endo180, since no protein was detected in parallel samples derived from uPARAP/Endo180-/- mice. The seven mAbs were tested for the ability to inhibit the uptake of radiolabeled collagen type I by primary mouse skin fibroblasts, a process reflecting a central step in the combined proteolytic and endocytic collagen degradation pathway (11,15). One of them, mAb 5f4, proved able to very

efficiently reduce the collagen internalization process (Fig. 1B). Although the assay conditions with protease treatment of the cells did inevitably leave a small amount of bound collagen on the outside of the cells (see Methods), thus preventing a complete isolation of the internalized radioactivity, the antibody reduced the amount of radioactivity to less than 25 %. Even more importantly, this level was very close to that obtained with fibroblasts from littermate uPARAP/Endo180 knockout mice. The same antibody did not affect the cellular internalization of holo-transferrin, an irrelevant, non-collagen protein that is internalized through clathrin-coated pits by means of the Transferrin receptor (44) (Fig. 1C). Thus, mAb 5f4 does not affect the general endocytosis machinery of the cells. One additional antibody was also inhibitory whereas the remainders were negative (results not shown). The inhibitory property of mAb 5f4 was further characterized and collagen internalization experiments with mouse fibroblasts revealed an approximate IC50 of 0.04 µg/ml (Fig. 1D), thus indicating a very potent blocking reagent. To directly visualize the effect of mAb 5f4 on the resulting degradation process, a different experimental system was applied, using fluorescence-labeled collagens. Like collagen type I, collagen type IV and gelatin (denatured collagen type I) are internalized by fibroblasts in a completely uPARAP/Endo180-dependent manner and can be used in fluorescence-labeled form for studies on endocytosis (10,11). uPARAP/Endo180 deficient (-/-) fibroblasts or littermate wildtype (uPARAP/Endo180+/+) fibroblasts were incubated with Oregon Green-labeled collagen type IV in the absence or presence of mAb 5f4 and the cellular uptake was monitored using fluorescence microscopy (Fig. 2). In the absence of mAb 5f4, internalized collagen was observed in uPARAP/Endo180+/+ fibroblasts in vesicular structures representing endosomes and lysosomes (Fig. 2A). As expected, no or little internalized collagen was found in the uPARAP/Endo180-/- fibroblasts (results not shown). The intracellular routing was indeed part of a degradation pathway because an even more pronounced vesicular accumulation of collagen was observed when the lysosomal cysteine protease inhibitor E64d was added (Fig. 2C). Both in the absence and presence of E64d, this accumulation of collagen was dramatically reduced when uPARAP/Endo180+/+ cells were incubated in the presence of mAb 5f4 (Fig. 2B and D), directly demonstrating the effect of

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

6

this mAb on the total degradation pathway. An antibody titration experiment with radiolabeled collagen type IV (Fig. 2G) revealed that the uptake of this type of collagen had the same high sensitivity to mAb 5f4 as that noted above with collagen type I. To test whether mAb 5f4 also blocked collagen turnover in human cells, we utilized the human osteosarcoma cell line MG63, a cell line known to express high levels of uPARAP/Endo180 (18,45). An internalization experiment using radiolabeled collagen type I revealed a blocking effect of mAb 5f4 with this human cell line that was similar to that found with uPARAP/Endo180+/+ mouse fibroblasts and a similar IC50 value was determined (Fig. 1E). Furthermore, when fluorescence-labeled gelatin was added to MG63 cells, the internalized protein accumulated in the endosomal/lysosomal compartments (Fig. 2E), whereas in the presence of mAb 5f4, this accumulation was clearly inhibited (Fig. 2F). Both with human and murine cells, even very low concentrations of antibody were sufficient to block the uptake of the fluorescence-labeled ligand (Supplemental Fig. 1), in complete accordance with the titration studies performed with radiolabeled collagens. Thus, the uptake of all of the collagen ligands tested in these cells displayed a strong sensitivity to mAb 5f4 against uPARAP/Endo180. These observations raised the question about the mechanism through which mAb 5f4 could counteract the function of uPARAP/Endo180 in collagen internalization. First, we utilized a purified system with surface plasmon resonance to test any blocking effect of the antibody against the direct interaction between uPARAP/Endo180 and collagen. Using an established BIAcore setup with recombinant uPARAP/Endo180 immobilized on a distinct catching monoclonal antibody, mAb 2h9F12 (11), we first ensured that this catching antibody did not prevent the subsequent binding of mAb 5f4 to uPARAP/Endo180 (results not shown). In the next step, we injected solubilized collagen type I into flow cells with immobilized uPARAP that was either unoccupied or saturated with mAb 5F4 (Supplemental Fig. 2). Somewhat surprisingly, this experiment showed that mAb 5f4 had no inhibitory effect on collagen binding. Consequently, we tested whether the antibody had an influence on the cellular uPARAP/Endo180 protein level. Mouse primary fibroblasts and human

MG63 cells were cultured in the presence or absence of mAb 5f4, after which the cellular level of uPARAP/Endo180 was assessed by Western blotting (Fig. 3). Strikingly, with both cell types, cultivation in the presence of the antibody led to a strongly reduced level of the collagen receptor. Thus, the effect of mAb 5f4 is similar to that observed with certain other antibodies against cell surface receptors which function through an apparent downregulation of their target antigen (46,47), an effect likely to reflect an antibody-induced failure of receptor recycling. We have previously demonstrated that the intracellular collagen turnover pathway is operative when fibroblasts act to remodel an insoluble collagen matrix. Thus, uPARAP/Endo180 is essential for the clearance of the initial collagen cleavage products that are released through the action of MT1-MMP when fibroblasts invade a trypsin-resistant collagen matrix (Fig. 4A) (11). This clearance defect results in the accumulation of defined collagen fragments in the conditioned media of the uPARAP/Endo180-/- fibroblasts (Fig 4B, lane 4) but not of the uPARAP/Endo180+/+ fibroblasts (Fig 4B, lane 3). Strikingly, incubation of uPARAP/Endo180+/+ fibroblasts with the mAb 5f4 led to the same accumulation of collagen fragments that were observed for the uPARAP/Endo180-/- fibroblasts (Fig 4B, lane 5). This demonstrates that, also in a composite cell culture assay of collagen degradation, it is possible to mimic uPARAP/Endo180 deficiency by incubation of uPARAP/Endo180+/+ fibroblasts with mAb 5f4. The role of uPARAP/Endo180 in collagen internalization by different cell types. A panel of human and murine cell lines of epithelial or mesenchymal origin (Table 1) were screened for their ability to internalize radiolabeled collagen. Simultaneously, for each cell line, the level of uPARAP/Endo180 expression was determined using a distinct, high affinity anti-uPARAP/Endo180 mAb, designated 2h9F12. As shown by previous BIAcore studies ((11) and results not shown), the interaction between uPARAP/Endo180 and this antibody is stable even at low pH, thereby precluding endosomal dissociation of the complex. Consequently, the total amount of cell bound mAb 2h9F12 on different cell types enables a determination of the relative amounts of uPARAP/Endo180 molecules. For each

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

7

cell line the collagen internalization was measured and the collagen internalization could then be plotted against the determined uPARAP/Endo180 levels (Fig. 5A). Strikingly, this analysis revealed a strong correlation between the uPARAP/Endo180 expression of the cells and their ability to internalize collagen (p=0.00018). As expected, the mesenchymal cell types proved much more efficient in internalizing collagen than the epithelial cells (Fig. 5A, empty dots). With the exception of rhabdomyosarcoma (RD) cells, all the mesenchymal cells were capable of efficient collagen internalization (with a read-out of more than 40% of the reference cell line MG63). The epithelial cell lines expressed low levels of uPARAP/Endo180 (Fig. 5A, filled dots) and all of them were incapable of efficient internalization of collagen. To make sure that the uPARAP/Endo180 level correlated with collagen internalization specifically, and not just with the general endocytic activity of the cells, we also examined the uptake of holo-transferrin (Fig. 5B). This analysis did not reveal any correlation between uPARAP/Endo180 level and the general endocytic activity of the cell lines. To examine whether uPARAP/Endo180 also on these cell types was directly responsible for the collagen uptake, the blocking uPARAP/Endo180 mAb 5f4 was utilized. Internalization of radiolabeled collagen type I was carried out in the presence or absence of mAb 5f4. In the presence of mAb 5f4, the collagen uptake was markedly reduced for all the cell lines capable of efficient collagen internalization (Fig. 5). As mentioned above, the mesenchymal RD cells expressed low levels of uPARAP/Endo180 and internalized low levels of collagen. The presence of mAb 5f4 did not reduce collagen internalization for this cell line. Of the epithelial cell lines, HeLa cells had the highest level of uPARAP/Endo180 expression, and, in fact, this epithelial cell line was the only one that displayed reduced collagen internalization in the presence of mAb 5f4. Beta1-integrins are not involved in the endocytosis of soluble collagen. Although collagen internalization was found to be a completely uPARAP/Endo180-dependent process in our experimental systems, we could not exclude the possibility that other receptors could be involved as well. Beta1-integrins are key mediators of cellular adhesion to collagen (48) and are required for the

phagocytic uptake of collagen-coated beads (49). Therefore, and because a central issue to be elucidated is the distinction between the present route of collagen degradation and the phagocytic uptake of particulate collagen, we studied the possible function of beta1-integrins in the internalization of solubilized, radiolabeled collagen. This was examined using beta1-integrin null mouse fibroblasts (GD25), as well as GD25 fibroblasts re-transfected with beta1-integrin (GD25-beta) (fig 7A). Both cell lines were capable of internalizing solubilized collagen and furthermore, collagen internalization could be markedly reduced by the presence of mAb 5f4 for both cell lines. Thus, also with these cells uPARAP/Endo180 has a decisive function in the collagen uptake mechanism. Beta1-integrin null fibroblasts (GD25) internalized collagen very efficiently (155% of MG63 cells under our experimental conditions). The efficient internalization in GD25 cells clearly demonstrated that beta1-integrins are not required for the uptake of solubilized collagen. Indeed, with the present fibroblast strains, the beta1-integrin re-transfected (GD25-beta) cells even internalized less collagen than GD25 cells. This difference in collagen uptake between the GD25 and the GD25-beta fibroblasts could be explained by the different levels of uPARAP/Endo180 expression (Fig. 7B) and was not caused by a general difference in their endocytic capacities (Fig. 7C). To examine the possibility that beta1-integrin independent collagen endocytosis was restricted to murine fibroblasts we analyzed the human osteosarcoma cell line MG63 (Fig. 7D). To investigate the role of beta1-integrin for collagen internalization in a human cell line we utilized the blocking beta1-integrin antibody 4B4 (12,13,50). Collagen internalization by MG63 cells was not affected by the addition of 4B4 (Fig. 7D, columns 3 and 4). To confirm this result we also utilized cyclic RGD peptide (13,36,51) to block beta1-integrin. In the presence of cyclic RGD peptide collagen internalization was likewise unaffected (Fig 7D, columns 5 and 6), demonstrating that also the human cell line MG63 is capable of beta1-integrin independent collagen endocytosis. Beta1-integrin dependence was also tested for the murine fibroblast cell line NIH/3T3 using blocking antibody and cyclic RGD peptide. This cell line was included in the analysis because of reported beta1-integrin mediated phagocytic collagen uptake by this cell line (52,53). However, in our assay of non-phagocytic collagen internalization we did not

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

8

observe any beta1-integrin dependence for this cell line (results not shown). The mannose receptor is responsible for collagen endocytosis in macrophages. In addition to fibroblasts, osteoblasts and chondrocytes, which are key players in collagen turnover in the healthy body (16,54,55), macrophages play a decisive role in the matrix degradation processes in inflammatory conditions (3,56,57). Interestingly, uPARAP/Endo180 expression has in certain cases been demonstrated on macrophages (58-60). This raised the question whether an uptake mechanism for solubilized collagen exists in macrophages and whether any such mechanism depends on uPARAP/Endo180 or different receptors. To examine the process of collagen endocytosis in macrophages, we isolated monocytes from human plasma and differentiated these cells to macrophages in vitro by cell culture for 8 days in the presence of GM-CSF. No uPARAP/Endo180 was detected on the undifferentiated monocytes, whereas a low level of uPARAP/Endo180 expression could indeed be observed after differentiation to macrophages (Supplemental Fig. 3). However, the amounts of uPARAP/Endo180 detected were very low as compared to MG63 cells (Fig. 8A). The macrophages were assayed for their ability to internalize collagen and in spite of the very low level of uPARAP/Endo180 expression, they were capable of internalizing collagen at levels comparable with those of MG63 cells (Fig. 8B). Addition of mAb 5f4 did not affect collagen internalization significantly (Fig. 8B, column 4), indicating that the macrophages were taking up the collagen in a process independent of uPARAP/Endo180. Interestingly, this process was also insensitive to blocking of beta1-integrins, as shown with the same reagents as used above (Fig. 8C). To confirm that the internalized collagen was routed to the lysosomes for degradation, we repeated the collagen internalization assay with inclusion of E64d (Fig. 8D). We have previously shown that this inhibitor retards the lysosomal degradation of collagen which, in the case of murine fibroblasts, leads to an approximately 2-fold increase in the amount of intracellular collagen under our experimental conditions (11). In the case of macrophages, addition of E64d led to an approximately four-fold increase in the amount of intracellular collagen. This large effect could be indicative of a high lysosomal collagen degradation activity in macrophages in the absence of inhibitor.

Various recent studies have demonstrated that the mannose receptor (MR), which belongs to the same receptor family as uPARAP/Endo180, is able to bind to collagen and to promote the uptake of solubilized fluorescent-labeled collagen (61,62). Interestingly, the above-mentioned monocyte differentiation process led to the expression of the MR on the resulting macrophages, as verified by flow cytometry analysis (Supplemental Fig. 3). To examine whether macrophages utilize the MR to internalize collagen, we isolated activated macrophages from the peritoneum of MR deficient mice (MR-/-) or littermate wildtype (MR+/+) mice. First, we showed that the routinely used MR ligand model, mannose-BSA, was internalized exclusively by the MR+/+ macrophages and not by the MR-/- macrophages (Fig. 8F), demonstrating that MR-dependent endocytosis processes are indeed ongoing during our standard assay conditions. Strikingly, in the subsequent collagen internalization assays, the MR-/- macrophages displayed a markedly reduced ability to internalize collagen relative to the MR+/+ cells (Fig. 8E), indicating a dominant function of MR in collagen endocytosis in this cell type. In contrast, neither MR+/+ nor MR-/- macrophages were affected by addition of mAb 5f4 (Fig. 8E). Altogether, our results show that members of the receptor family comprising uPARAP/Endo180 and MR are dominant mediators of the endocytic uptake of solubilized collagen, with the identity of the active receptor differing between different cell types.

DISCUSSION

In this study we have examined the endocytosis of solubilized collagen in a panel of mesenchymal and epithelial cell lines and in human and murine macrophages. We have previously demonstrated that this endocytic process models the non-phagocytic uptake of the primary collagen cleavage products (“¼” and “¾” fragments), that are generated by the action of collagenolytic proteases in an organized degradation pathway (11). To enable analysis of the specific role of the collagen internalization receptor uPARAP/Endo180 in all of the cell types studied, we developed a monoclonal antibody against uPARAP/Endo180 that works to deplete the cells for the receptor. This antibody, designated mAb 5f4, very efficiently prevents the uPARAP/Endo180-dependent collagen uptake in both murine and human cells.

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

9

The analysis of a range of established cell lines revealed a striking correlation between the cellular collagen internalization capability and the cellular protein level of uPARAP/Endo180. For all cell lines, which displayed efficient collagen internalization, the addition of mAb 5f4 led to a pronounced reduction in the amount of internalized collagen. The epithelial cell lines internalized much less collagen than the mesenchymal cells and they expressed lower amounts of uPARAP/Endo180. Among the epithelial cell lines, HeLa cells displayed the highest expression level of uPARAP/Endo180 and interestingly, this cell line did internalize less collagen in the presence of mAb 5f4 and was the only epithelial cell type with this property. Among the examined cell types we found that the gingival fibroblast cell line HGF-1 expressed the highest protein level of uPARAP/Endo180. As expected, this cell line displayed efficient and uPARAP/Endo180-dependent collagen internalization. An altered collagen metabolism by gingival fibroblasts is known to be involved in such pathological conditions as periodontal disease and gingival overgrowth, which are characterized by increased and decreased collagen degradation, respectively. In this cell type, it has long been recognized that intracellular collagen degradation is a central route of turnover, but so far, only integrins have been suggested as mediators of this degradation pathway (12,49,63). Our study reveals that uPARAP/Endo180 is required for the endocytosis of collagen by gingival fibroblasts, thus potentially opening new therapeutic options for future treatment of periodontal disease. The distinction between different mechanisms of collagen uptake and the identification of the receptors involved are two important issues. The beta1-integrins are an additional type of collagen receptors, which have been shown to be involved in processes of collagen internalization (12,49,53). However, those studies have focused entirely on a phagocytic uptake mechanism, i.e. the uptake of collagen-coated beads. A wide range of different cell types express beta1-integrins (12,48,53), including many of the cell lines that we have found in this study to be capable of non-phagocytic, uPARAP/Endo180-dependent collagen uptake. Thus, some cell lines appear to possess the ability to internalize collagen in both a phagocytic and a non-

phagocytic manner, notably including gingival fibroblasts and NIH-3T3 cells. However, although our blocking studies with mAb 5f4 on the non-phagocytic pathway did document a central role of uPARAP/Endo180, they did not exclude that beta1-integrins could also be involved in this collagen uptake process, since the two receptors might cooperate. To study this possibility, we examined the non-phagocytic collagen uptake by fibroblasts derived from beta1-integrin deficient mice (39). We found that these fibroblasts, termed GD25, displayed efficient collagen internalization and that this uptake was completely uPARAP/Endo180-dependent. That beta1-integrins were indeed not involved in the uptake of collagen in our assay system was further substantiated by the fact that GD25 fibroblasts re-transfected with beta1-integrin (GD25-beta) (64) actually internalized less collagen than the GD25 fibroblasts. This difference is most likely a consequence of clonal variations between the two cell lines, resulting in different levels of uPARAP/Endo180 expression. The analyses using GD25 fibroblasts are in line with previous observations where antibody-mediated blocking of beta1-integrin on murine skin fibroblasts did not affect the uptake of solubilized collagen (15). The distinction between these mechanisms of collagen internalization is supported by a recent study where Shi et al. examined the uptake of soluble collagen and of insoluble polymerized collagen (14). These authors found that beta1-integrins are not involved in the endocytosis of soluble collagen, in agreement with our results, whereas they are indeed dominant mediators of the internalization of the collagen originating from an insoluble collagen-matrix, in consistence with the studies cited above on collagen phagocytosis. Furthermore, Shi et al. found that uPARAP/Endo180 is indeed also involved in a particular turnover mechanism for insoluble matrix-collagen that is sensitive to matrix metalloprotease inhibitors (14). This points to a sequential degradation mechanism for matrix-collagen in agreement with our previous studies (11). Our present work suggests that this pathway may be a widespread mechanism in many cell types. The existence of two distinct mechanisms for collagen uptake leads to the question about the role of these two collagen degradation pathways in vivo.

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

10

Intracellular degradation of collagen has been known for several decades to be operative in vivo in a number of physiological and pathological contexts (63) but the identity of the responsible receptors has been limited to speculation. Recently, however, a number of studies have confirmed that uPARAP/Endo180 does indeed take part in collagen turnover processes in vivo. Crooked Tail Syndrome is a severe genetic disease observed in the inbred “Belgian Blue” strain of cattle, which results in massive bone defects that necessitate the euthanization of the affected animals. In a recent genetic study, the underlying cause of the disease was identified as a frame-shift mutation in the gene encoding uPARAP/Endo180, leading to the expression of a non-functional protein (20). Expression of uPARAP/Endo180 has also been demonstrated during bone development in normal mice (23) but in uPARAP/Endo180 knockout mice in the absence of challenge, only a slightly reduced bone length has been observed ((16) and Madsen et al., unpublished). However, in combination with deficiency for MT1-MMP, an important collagenolytic protease, uPARAP/Endo180 deficiency was found to lead to fatal bone defects (16). Thus, the collagen turnover processes of uPARAP/Endo180 play a central role in bone development in mice as well as in cattle. In a pathological context, uPARAP/Endo180 expression has been observed in the tumor stroma of multiple types of cancer, including breast cancer (27). The functional implication of uPARAP/Endo180 in breast cancer progression was investigated using a mouse model of genetically induced mammary cancer (MMTV-PymT model) (19). In this cancer model, uPARAP/Endo180 deficiency leads to delayed growth of the tumors and, interestingly, also to large accumulations of intratumoral collagen, demonstrating that uPARAP/Endo180 participates in the turnover of collagen in this pathological condition. uPARAP/Endo180 belongs to a protein family comprising three other receptors, the mannose receptor (MR), phospholipase A2 receptor (PLA2R) and DEC-205. All four receptors share a common protein domain composition, which includes a well-conserved fibronectin type II domain (65,66). This domain is believed to be the most important element for the interaction between uPARAP/Endo180 and collagen. MR has for many years been linked to the innate immune system as a receptor capable of binding to carbohydrates on the surface of certain

pathogens, thereby promoting their phagocytosis (67). Recently, however, MR has also been reported to bind and internalize collagen in vitro (61,62) and to be responsible for the clearance of denatured collagen from the circulation in vivo (68). MR is primarily expressed by macrophages but is also observed on certain other cell types such as the specialized endothelial cells of the liver sinusoids (67,69). Macrophages are known to be involved in promoting the degradation of the extracellular matrix in multiple pathological processes (3,56,57,70). In this work we have examined collagen endocytosis by macrophages to study the relative role of uPARAP/Endo180 and MR in the non-phagocytic collagen degradation pathway. The differentiation of human blood monocytes to macrophages in vitro led to a dramatic upregulation of MR and also a moderate upregulation of uPARAP/Endo180. Further determination of the cellular level of uPARAP/Endo180 did, however, reveal that the macrophages expressed less than 20% of the reference cell line MG63. Strikingly, these macrophages proved capable of efficient collagen internalization, but were insensitive to addition of mAb 5f4 against uPARAP/Endo180. Previous studies using fluorescence-labeled solubilized collagen suggest that MR is the receptor responsible for collagen internalization in the case of macrophages (62). To clarify whether this was also the case in our assay system, we isolated peritoneal macrophages from MR-/- mice or from littermate MR+/+ mice. Collagen internalization assays with these primary cells revealed a clear dependency on MR for collagen internalization. Just like the situation observed with mesenchymal cells, we did not observe any beta1-integrin dependence for the collagen uptake by cultured macrophages. Altoghether, these observations suggest that the mannose receptor could be critical for the degradation of collagen in pathological conditions, which involve increased macrophage influx and/or activation. Such conditions include cancer, fibrosis and arthritis (3,57,70). Subsets of macrophages have been identified as uPARAP/Endo180 positive in vivo in certain locations (58-60). To this end, we cannot rule out the possibility that our cultured macrophages represent a certain subtype of macrophages, whereas other subtypes of macrophages could display a higher level of uPARAP/Endo180 expression and

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

11

be capable of internalizing collagen in a uPARAP/Endo180-dependent manner. This study reveals that uPARAP/Endo180 and the mannose receptor are two major mediators of the non-phagocytic collagen degradation pathway, with uPARAP/Endo180 acting primarily on mesenchymal cells and MR on macrophages. It remains a possibility that the other members of the same protein family, PLA2R and DEC-205 could have a similar function on other cell types. In fact, the PLA2R has been found to interact with collagen in vitro (71) and we speculate that this interaction could likewise be connected to intracellular degradation of collagen. Altogether, our work points to a previously underestimated role of the mannose receptor protein family members in the turnover of extracellular matrices. Since these breakdown processes are important in malignant as well as non-malignant diseases this concept opens a new range of therapeutic strategies.

Acknowledgements- The excellent technical assistance of Suzanne K. Møller and Katharina H. Stegmann is gratefully acknowledged. This work was supported by the Danish Cancer Society, the Danish Medical Research Council, the Danish Cancer Research Foundation, the Lundbeck Foundation, the Danish National Research Foundation (Danish-Chinese Center for Proteases and Cancer) and the European Community’s Seventh Framework Programme FP7/2007-2011 under grant agreement n°201279 (N. B.), by the Lundbeck Foundation and the “Grosserer Alfred Nielsen og Hustrus” foundation (L. H. E.) and by the NIDCR Intramural Research Program (A. M. and T. H. B.). The work was supported by personal grants from Copenhagen University Hospital (D. H. M. and H. J. J.) and from the University of Copenhagen, Faculty of Science (S. I.).

REFERENCES

1. Milner, J. M. and Cawston, T. E. (2005) Curr. Drug Targets. Inflamm. Allergy. 4, 363-375 2. Holmbeck, K. and Szabova, L. (2006) Birth Defects Res. C. Embryo. Today. 78, 11-23 3. Friedman, S. L. (2008) Gastroenterology. 134, 1655-1669 4. Rowe, R. G. and Weiss, S. J. (2009) Annu. Rev. Cell Dev. Biol. 25, 567-595 5. Pataridis, S., Eckhardt, A., Mikulikova, K., Sedlakova, P., and Miksik, I. (2008) J. Sep. Sci. 31,

3483-3488 6. Ottani, V., Martini, D., Franchi, M., Ruggeri, A., and Raspanti, M. (2002) Micron. 33, 587-596 7. Saftig, P., Hunziker, E., Wehmeyer, O., Jones, S., Boyde, A., Rommerskirch, W., Moritz, J. D.,

Schu, P., and von, F. K. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 13453-13458 8. Hotary, K., Li, X. Y., Allen, E., Stevens, S. L., and Weiss, S. J. (2006) Genes Dev. 20, 2673-2686 9. Shi, J., Son, M. Y., Yamada, S., Szabova, L., Kahan, S., Chrysovergis, K., Wolf, L., Surmak, A., and

Holmbeck, K. (2008) Dev. Biol. 313, 196-209 10. Kjoller, L., Engelholm, L. H., Hoyer-Hansen, M., Dano, K., Bugge, T. H., and Behrendt, N. (2004)

Exp. Cell Res. 293, 106-116 11. Madsen, D. H., Engelholm, L. H., Ingvarsen, S., Hillig, T., Wagenaar-Miller, R. A., Kjoller, L.,

Gardsvoll, H., Hoyer-Hansen, G., Holmbeck, K., Bugge, T. H., and Behrendt, N. (2007) J. Biol. Chem. 282, 27037-27045

12. Segal, G., Lee, W., Arora, P. D., McKee, M., Downey, G., and McCulloch, C. A. (2001) J. Cell Sci. 114, 119-129

13. Lee, J. W., Qi, W. N., and Scully, S. P. (2002) J. Orthop. Res. 20, 66-75 14. Shi, F., Harman, J., Fujiwara, K., and Sottile, J. (2010) Am. J. Physiol Cell Physiol. 298, C1265-

C1275 15. Engelholm, L. H., List, K., Netzel-Arnett, S., Cukierman, E., Mitola, D. J., Aaronson, H., Kjoller, L.,

Larsen, J. K., Yamada, K. M., Strickland, D. K., Holmbeck, K., Dano, K., Birkedal-Hansen, H., Behrendt, N., and Bugge, T. H. (2003) J. Cell Biol. 160, 1009-1015

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

12

16. Wagenaar-Miller, R. A., Engelholm, L. H., Gavard, J., Yamada, S. S., Gutkind, J. S., Behrendt, N., Bugge, T. H., and Holmbeck, K. (2007) Mol. Cell Biol. 27, 6309-6322

17. Isacke, C. M., van der Geer, P., Hunter, T., and Trowbridge, I. S. (1990) Mol. Cell Biol. 10, 2606-2618

18. Howard, M. J. and Isacke, C. M. (2002) J. Biol. Chem. 277, 32320-32331 19. Curino, A. C., Engelholm, L. H., Yamada, S. S., Holmbeck, K., Lund, L. R., Molinolo, A. A.,

Behrendt, N., Nielsen, B. S., and Bugge, T. H. (2005) J. Cell Biol. 169, 977-985 20. Fasquelle, C., Sartelet, A., Li, W., Dive, M., Tamma, N., Michaux, C., Druet, T., Huijbers, I. J.,

Isacke, C. M., Coppieters, W., Georges, M., and Charlier, C. (2009) PLoS. Genet. 5, e1000666 21. Wu, K., Yuan, J., and Lasky, L. A. (1996) J. Biol. Chem. 271, 21323-21330 22. Behrendt, N. (2004) Biol. Chem. 385, 103-136 23. Engelholm, L. H., Nielsen, B. S., Netzel-Arnett, S., Solberg, H., Chen, X. D., Lopez Garcia, J. M.,

Lopez-Otin, C., Young, M. F., Birkedal-Hansen, H., Dano, K., Lund, L. R., Behrendt, N., and Bugge, T. H. (2001) Lab Invest. 81, 1403-1414

24. Howard, M. J., Chambers, M. G., Mason, R. M., and Isacke, C. M. (2004) Osteoarthritis. Cartilage. 12, 74-82

25. Huijbers, I. J., Iravani, M., Popov, S., Robertson, D., Al-Sarraj, S., Jones, C., and Isacke, C. M. (2010) PLoS. One. 5, e9808

26. Kogianni, G., Walker, M. M., Waxman, J., and Sturge, J. (2009) Eur. J. Cancer. 45, 685-693 27. Schnack, N. B., Rank, F., Engelholm, L. H., Holm, A., Dano, K., and Behrendt, N. (2002) Int. J.

Cancer. 98, 656-664 28. Sulek, J., Wagenaar-Miller, R. A., Shireman, J., Molinolo, A., Madsen, D. H., Engelholm, L. H.,

Behrendt, N., and Bugge, T. H. (2007) J. Histochem. Cytochem. 55, 347-353 29. Wienke, D., Davies, G. C., Johnson, D. A., Sturge, J., Lambros, M. B., Savage, K., Elsheikh, S. E.,

Green, A. R., Ellis, I. O., Robertson, D., Reis-Filho, J. S., and Isacke, C. M. (2007) Cancer Res. 67, 10230-10240

30. Engelholm, L. H., Ingvarsen, S., Jurgensen, H. J., Hillig, T., Madsen, D. H., Nielsen, B. S., and Behrendt, N. (2009) Front Biosci. 14, 2103-2114

31. Jogi, A., Pass, J., Hoyer-Hansen, G., Lund, L. R., Nielsen, B. S., Dano, K., and Romer, J. (2007) J. Thromb. Haemost. 5, 1936-1944

32. Honore, C., Rorvig, S., Munthe-Fog, L., Hummelshoj, T., Madsen, H. O., Borregaard, N., and Garred, P. (2008) Mol. Immunol. 45, 2782-2789

33. Lee, S. J., Evers, S., Roeder, D., Parlow, A. F., Risteli, J., Risteli, L., Lee, Y. C., Feizi, T., Langen, H., and Nussenzweig, M. C. (2002) Science. 295, 1898-1901

34. Lund, L. R. and Dano, K. (1992) FEBS Lett. 298, 177-181 35. Hansen, L. V., Gardsvoll, H., Nielsen, B. S., Lund, L. R., Dano, K., Jensen, O. N., and Ploug, M.

(2004) Biochem. J. 380, 845-857 36. Hillig, T., Engelholm, L. H., Ingvarsen, S., Madsen, D. H., Gardsvoll, H., Larsen, J. K., Ploug, M.,

Dano, K., Kjoller, L., and Behrendt, N. (2008) J. Biol. Chem. 283, 15217-15223 37. Nielsen, B. S., Lund, L. R., Christensen, I. J., Johnsen, M., Usher, P. A., Wulf-Andersen, L.,

Frandsen, T. L., Dano, K., and Gundersen, H. J. (2001) Am. J. Pathol. 158, 1997-2003 38. Romer, J., Pyke, C., Lund, L. R., Eriksen, J., Kristensen, P., Ronne, E., Hoyer-Hansen, G., Dano, K.,

and Brunner, N. (1994) Int. J. Cancer. 57, 553-560 39. Fassler, R., Pfaff, M., Murphy, J., Noegel, A. A., Johansson, S., Timpl, R., and Albrecht, R. (1995)

J. Cell Biol. 128, 979-988 40. Holmbeck, K., Bianco, P., Caterina, J., Yamada, S., Kromer, M., Kuznetsov, S. A., Mankani, M.,

Robey, P. G., Poole, A. R., Pidoux, I., Ward, J. M., and Birkedal-Hansen, H. (1999) Cell. 99, 81-92 41. Claesson, M. H., Endel, B., Ulrik, J., Pedersen, L. O., Skov, S., and Buus, S. (1994) Scand. J.

Immunol. 40, 257-264 42. Declerck, P. J., Carmeliet, P., Verstreken, M., De, C. F., and Collen, D. (1995) J. Biol. Chem. 270,

8397-8400 43. Ingvarsen, S., Madsen, D. H., Hillig, T., Lund, L. R., Holmbeck, K., Behrendt, N., and Engelholm,

L. H. (2008) Biol. Chem. 389, 943-953

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

13

44. Watts, C. and Marsh, M. (1992) J. Cell Sci. 103, 1-8 45. Wienke, D., MacFadyen, J. R., and Isacke, C. M. (2003) Mol. Biol. Cell. 14, 3592-3604 46. von, F. K., Gieselmann, V., and Hasilik, A. (1984) EMBO J. 3, 1281-1286 47. Schwartz, A. L., Ciechanover, A., Merritt, S., and Turkewitz, A. (1986) J. Biol. Chem. 261, 15225-

15232 48. Barczyk, M., Carracedo, S., and Gullberg, D. (2010) Cell Tissue Res. 339, 269-280 49. Lee, W., Sodek, J., and McCulloch, C. A. (1996) J. Cell Physiol. 168, 695-704 50. Hegerfeldt, Y., Tusch, M., Brocker, E. B., and Friedl, P. (2002) Cancer Res. 62, 2125-2130 51. Ruoslahti, E. (1996) Annu. Rev. Cell Dev. Biol. 12, 697-715 52. Arora, P. D., Fan, L., Sodek, J., Kapus, A., and McCulloch, C. A. (2003) Exp. Cell Res. 286, 366-

380 53. Arora, P. D., Marignani, P. A., and McCulloch, C. A. (2008) Am. J. Physiol Cell Physiol. 295, C130-

C137 54. Blair, H. C., Zaidi, M., and Schlesinger, P. H. (2002) Biochem. J. 364, 329-341 55. Wang, J. H., Thampatty, B. P., Lin, J. S., and Im, H. J. (2007) Gene. 391, 1-15 56. Rizas, K. D., Ippagunta, N., and Tilson, M. D., III (2009) Cardiol. Rev. 17, 201-210 57. Szekanecz, Z. and Koch, A. E. (2007) Curr. Opin. Rheumatol. 19, 289-295 58. Honardoust, H. A., Jiang, G., Koivisto, L., Wienke, D., Isacke, C. M., Larjava, H., and Hakkinen, L.

(2006) Histopathology. 49, 634-648 59. Sheikh, H., Yarwood, H., Ashworth, A., and Isacke, C. M. (2000) J. Cell Sci. 113, 1021-1032 60. Ye, Q., Xing, Q., Ren, Y., Harmsen, M. C., and Bank, R. A. (2010) Eur. Cell Mater. 20, 197-209 61. Napper, C. E., Drickamer, K., and Taylor, M. E. (2006) Biochem. J. 395, 579-586 62. Martinez-Pomares, L., Wienke, D., Stillion, R., McKenzie, E. J., Arnold, J. N., Harris, J., McGreal,

E., Sim, R. B., Isacke, C. M., and Gordon, S. (2006) Eur. J. Immunol. 36, 1074-1082 63. Everts, V., van der Zee, E., Creemers, L., and Beertsen, W. (1996) Histochem. J. 28, 229-245 64. Wennerberg, K., Lohikangas, L., Gullberg, D., Pfaff, M., Johansson, S., and Fassler, R. (1996) J.

Cell Biol. 132, 227-238 65. East, L. and Isacke, C. M. (2002) Biochim. Biophys. Acta. 1572, 364-386 66. Behrendt, N., Jensen, O. N., Engelholm, L. H., Mortz, E., Mann, M., and Dano, K. (2000) J. Biol.

Chem. 275, 1993-2002 67. Martinez-Pomares, L., Linehan, S. A., Taylor, P. R., and Gordon, S. (2001) Immunobiology. 204,

527-535 68. Malovic, I., Sorensen, K. K., Elvevold, K. H., Nedredal, G. I., Paulsen, S., Erofeev, A. V.,

Smedsrod, B. H., and McCourt, P. A. (2007) Hepatology. 45, 1454-1461 69. Smedsrod, B., Melkko, J., Risteli, L., and Risteli, J. (1990) Biochem. J. 271, 345-350 70. Mantovani, A., Schioppa, T., Porta, C., Allavena, P., and Sica, A. (2006) Cancer Metastasis Rev. 25,

315-322 71. Ancian, P., Lambeau, G., and Lazdunski, M. (1995) Biochemistry. 34, 13146-13151 72. Horoszewicz, J. S., Leong, S. S., Chu, T. M., Wajsman, Z. L., Friedman, M., Papsidero, L., Kim, U.,

Chai, L. S., Kakati, S., Arya, S. K., and Sandberg, A. A. (1980) Prog. Clin. Biol. Res. 37:115-32., 115-132

73. Cailleau, R., Young, R., Olive, M., and Reeves, W. J., Jr. (1974) J. Natl. Cancer Inst. 53, 661-674 74. Fogh, J., Fogh, J. M., and Orfeo, T. (1977) J. Natl. Cancer Inst. 59, 221-226 75. SCHERER, W. F., SYVERTON, J. T., and GEY, G. O. (1953) J. Exp. Med. 97, 695-710 76. Brooks, S. C., Locke, E. R., and Soule, H. D. (1973) J. Biol. Chem. 248, 6251-6253 77. Graham, F. L., Abrahams, P. J., Mulder, C., Heijneker, H. L., Warnaar, S. O., De Vries, F. A., Fiers,

W., and Van Der Eb, A. J. (1975) Cold Spring Harb. Symp. Quant. Biol. 39 Pt 1:637-50., 637-650 78. Bertram, J. S. and Janik, P. (1980) Cancer Lett. 11, 63-73 79. Fidler, I. J. (1973) Nat. New Biol. 242, 148-149 80. McAllister, B. S., Leeb-Lundberg, L. M., Javors, M. A., and Olson, M. S. (1993) Arch. Biochem.

Biophys. 304, 294-301 81. Billiau, A., Edy, V. G., Heremans, H., Van, D. J., Desmyter, J., Georgiades, J. A., and De, S. P.

(1977) Antimicrob. Agents Chemother. 12, 11-15

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

14

82. Jacobs, J. P., Jones, C. M., and Baille, J. P. (1970) Nature. 227, 168-170 83. Rasheed, S., Nelson-Rees, W. A., Toth, E. M., Arnstein, P., and Gardner, M. B. (1974) Cancer. 33,

1027-1033 84. McAllister, R. M., Melnyk, J., Finkelstein, J. Z., Adams, E. C., Jr., and Gardner, M. B. (1969)

Cancer. 24, 520-526 85. SANFORT, K. K., Merwin, R. M., Hobbs, G. L., and Young, J. M. (1959) J. Natl. Cancer Inst. 23,

1035-1059 86. Jainchill, J. L., Aaronson, S. A., and Todaro, G. J. (1969) J. Virol. 4, 549-553

FOOTNOTES The abbriviations used are: ECM, extracellular matrix; uPARAP, urokinase plasminogen activator receptor- associated protein; MMP, matrix metalloprotease; MT1-MMP, membrane type 1 matrix metalloprotease; mAb, monoclonal antibody; TNP, tri-nitrophenyl; PE, phycoerythrin; BSA, bovine serum albumin; FITC, fluorescein isothiocyanate; MR, mannose receptor; MMTV-PymT, mouse mammary tumor virus – polyoma middle T; PLA2R, phospholipase A2 receptor.

FIGURE LEGENDS Table 1. Established cell lines included in the study of collagen uptake. Fig. 1. anti-uPARAP/Endo180 mAb 5f4 inhibits cellular collagen internalization. A, mAb 5f4 specifically recognizes uPARAP/Endo180. Detergent extracts of cultured fibroblasts isolated from newborn mice (left panel) or mouse heart and lung (right panel) were analyzed by Western blotting, using mAb 5f4 as the primary antibody. In each panel, samples from wildtype (uPARAP+/+) and uPARAP/Endo180 deficient (uPARAP-/-) mice were run in parallel lanes. The electrophoretic mobility of Mr marker proteins is indicated to the left. uPARAP/Endo180 migrates with an apparent Mr of 180 kDa. B, mAb 5f4 inhibits collagen internalization by murine fibroblasts. Primary fibroblasts from wildtype (uPARAP/Endo180+/+) mice (dark grey columns) or littermate uPARAP/Endo180-/- mice (light grey columns) were allowed to internalize radiolabeled soluble collagen I for 4 hours in the absence of antibody or in the presence of 10 µg/ml mAb 5f4 (hatched columns). C, Anti-uPARAP/Endo180 mAb 5f4 does not affect internalization of holo-transferrin. Murine fibroblast cultures were assayed as in B, but using radiolabeled holo-transferrin instead of collagen I. D, Anti-uPARAP/Endo180 mAb 5f4 inhibits collagen internalization in a dose-dependent manner. Murine primary fibroblast cultures were allowed to internalize radiolabeled soluble collagen I in the absence of antibody, in the presence of mAb 5f4 at concentrations ranging from 0.01 µg/ml to 100 µg/ml or in the presence of 100 µg/ml of a monoclonal isotype matched irrelevant control antibody (anti-TNP). uPARAP/Endo180-/- fibroblasts (light grey column) were included in the analysis for comparison. A half-maximum inhibition was obtained with an approximate concentration of 0.04 µg/ml of mAb 5f4. Both in B, C and D, the internalized radioactivity in untreated uPARAP/Endo180+/+ fibroblasts was defined as 100% internalization. E, Anti-uPARAP/Endo180 mAb 5f4 inhibits collagen internalization by human MG63 cells. An experiment was performed as in B, but using the human osteosarcoma cell line MG63 instead of primary murine fibroblasts. Internalization by MG63 cells in the absence of antibody was defined as 100% internalization. Note that a similar inhibitory efficacy of mAb 5f4 was observed with human and mouse cells. For B-E, all samples were analyzed in triplicates. Error bars indicate standard deviations. Fig. 2. Anti-uPARAP/Endo180 mAb 5f4 prevents the accumulation of collagen in intracellular vesicles. A-D, The intracellular accumulation of fluorescent-labeled collagen type IV in murine fibroblasts is prevented by anti-uPARAP/Endo180 mAb 5f4. Oregon Green labeled collagen IV was added to primary fibroblast cultures derived from uPARAP/Endo180+/+ mice, after which the cells were cultured for 18 hours in the absence of the lysosomal protease inhibitor E64d (A and B) or in the presence of 20 µM E64d (C and D). The internalization of collagen was carried out in the absence of antibody (A and C) or in the presence of 10

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

15

µg/ml mAb 5f4 (B and D). E-F, Anti-uPARAP/Endo180 mAb 5f4 prevents the intracellular accumulation of fluorescent-labeled gelatin in the human osteosarcoma cell line MG63. Oregon Green labeled gelatin was added to cultured MG63 cells in the presence of E64d. Internalization was carried out for 20 hours in the absence of antibody (E) or in the presence of 10 µg/ml mAb 5f4 (F). G, Cellular uptake of collagen IV is equally sensitive to mAb 5f4 as the uptake of collagen I. The mAb 5f4 dose dependence of collagen IV uptake was measured using radiolabeled collagen ligand. The conditions were the same as used in Fig. 1D, except that the ligand was 125I-labeled collagen IV. Fig. 3. Downregulation of the uPARAP/Endo180 protein level by mAb 5f4. Primary mouse fibroblasts (A) or human MG63 osteosarcoma cells (C) were cultured in the presence of mAb 5f4 or anti-TNP control mAb, after which detergent lysates of the cells were analyzed by Western blotting using 125I-labeled anti-uPARAP/Endo180 mAb 2h9F12 (upper panels) or SDS-PAGE and Coomassie-staining as loading control (lower panels). The quantification of band intensities in fibroblast lysates (A) is depicted in diagram B, and the band intensities in MG63 lysates (C) is depicted in diagram D. Fig. 4. Anti-uPARAP/Endo180 mAb 5f4 treatment mimics uPARAP/Endo180 deficiency in a composite assay of collagen degradation. A, Schematic illustration of the experimental setup. A collagen matrix was reconstituted by polymerization of acid-extracted collagen type I in which trace amounts of radiolabeled collagen type I was included. Fibroblasts were cultured on top of the collagen matrix for 5 days after which the conditioned culture supernatants were harvested and analyzed by non-reducing SDS-PAGE, followed by phosphorimaging analysis of the polyacrylamide-gel for the localization of specific collagen fragments released from the collagen matrix. B, Anti-uPARAP/Endo180 mAb 5f4 leads to extracellular accumulation of collagen degradation products. The culture supernatants from the following cells are shown: lane 3, Untreated uPARAP/Endo180+/+ cells; lane 4, untreated uPARAP/Endo180-/- cells; lane 5, uPARAP/Endo180+/+ cells cultured in the presence of 50 µg/ml mAb 5f4. The following purified reference proteins are shown: lane 1, 125I-labeled, intact collagen type I; lane 2, 125I-labeled, cleaved collagen type I. The positions of 1⁄4 and 3⁄4 collagen degradation fragments are indicated at right. Fig. 5. uPARAP/Endo180 expression correlates with collagen internalization in a variety of cell types. A, Correlation between uPARAP/Endo180 expression and collagen internalization. Fifteen epithelial (filled dots) and mesenchymal cell lines (empty dots), in addition to uPARAP/Endo180+/+ and uPARAP/Endo180-/- fibroblasts, were assayed for the expression of uPARAP/Endo180 and the ability to internalize radiolabeled collagen. The level of uPARAP/Endo180 expression was determined as the amount of cell bound radio-labeled anti-uPARAP/Endo180 mAb 2h9F12. Collagen internalization was assayed as in Fig. 1. MG63 cells were used as a reference cell line for the normalization of both collagen internalization and the level of uPARAP/Endo180 expression. Each cell line is represented as one point in the scatterplot, with the relative uPARAP/Endo180 level assigned to the x-axis and the collagen internalization activity assigned to the y-axis. A correlation analysis revealed a Pearson correlation coefficient r=0.77 and p=0.00018. A regression line is included in the graph. B, No correlation between uPARAP/Endo180 expression and holo-transferrin internalization. The same cell lines as in A were also assayed for the ability to internalize radiolabeled holo-transferrin. MG63 cells were used as a reference cell line for the normalization of holo-transferrin internalization. A scatterplot similar to the one in A was generated but with holo-transferrin internalization assigned to the y-axis. All samples were analyzed in triplicates. Error bars indicate standard deviations. Fig. 6. uPARAP/Endo180 mediates collagen internalization in a variety of cell types. Collagen internalization by a variety of established cell lines is inhibited by mAb 5f4. Collagen internalization was measured for each cell line used in Fig 4. Internalization was carried out in the absence of antibody (black columns) or in the presence of 10 µg/ml of mAb 5f4 (grey columns). The cell lines are ranked in the diagram according to their level of uPARAP/Endo180 expression, with the highest expressing cells at the left. MG63 cells were used as a reference cell line for the normalization of both collagen internalization and the level of uPARAP/Endo180 expression. All samples were analyzed in triplicates. Error bars indicate standard deviations.

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

16

Fig. 7. Beta1-integrins are not involved in the internalization of soluble collagen. A, Murine beta1-integrin null fibroblasts are capable of internalizing collagen. Murine beta1-integrin-deficient fibroblasts (GD25)(black columns) and beta1-integrin retransfected fibroblasts (GD25-beta)(grey columns) were analyzed for their ability to internalize radiolabeled soluble collagen I in the absence of antibody or in the presence of 10 µg/ml mAb 5f4 (hatched columns). The collagen internalization assay was performed as described in Fig. 1. B, uPARAP/Endo180 expression correlates with collagen internalization efficiency. The relative levels of uPARAP/Endo180 expression were determined for GD25 and GD25-beta fibroblasts as described in Fig. 4. C, GD25 and GD25-beta fibroblasts have the same overall endocytic capacity. An internalization assay was performed with radiolabeled holo-transferrin as in Fig. 1B. D, MG63 cells internalize collagen in a beta1-integrin independent process. MG63 cells were analyzed for their ability to internalize labeled soluble collagen I in the absence of any exogenous reagents (column 1), or in the presence of 10 µg/ml of mAb 5f4 (column 2), 2 µg/ml anti-beta1 mAb 4B4 (column 3), 10 µg/ml anti-beta1 mAb 4B4 (column 4), 50 µM cyclic RGD peptide (column 5) or 200 µM cyclic RGD peptide (column 6). A-D, MG63 cells were in all cases included in parallel analyses and used as a reference for the normalization of the data. All samples were analyzed in triplicates. Error bars indicate standard deviations. Fig. 8. The mannose receptor (MR) governs collagen internalization in macrophages. A-D, Human blood monocytes were differentiated to macrophages in vitro. A, Cultured macrophages express low amounts of uPARAP/Endo180. The relative level of uPARAP/Endo180 expression by cultured macrophages was based on the amount of cell bound radio-labeled anti-uPARAP/Endo180 mAb 2h9F12 as in Fig. 4. MG-63 cells were included as a normalization reference. B, Macrophages internalize collagen in a uPARAP/Endo180-independent process. The internalization of radiolabeled collagen type I was measured for MG63 cells (columns 1 and 2) and macrophages (columns 3 and 4) in the absence (columns 1 and 3) or presence (columns 2 and 4) of 10 µg/ml of mAb 5f4. Internalization by MG63 cells in the absence of antibody was defined as 100% internalization. C, The uptake of collagen in macrophages is independent of beta1-integrins. The internalization of radiolabeled collagen type I was measured in cultured human macrophages in the absence of exogenous reagents (column 1), or in the presence of 10 µg/ml anti-beta1 mAb 4B4 (column 2), or 200 µM cyclic RGD peptide (column 3). D, Internalized collagen is degraded by lysosomal cysteine proteases. The amount of collagen type I internalized by human macrophages was measured in the absence of protease inhibitor (column 1) or in the presence of 20 µM E64d (column 2). Internalization by untreated macrophages was defined as 100% internalization. E, Macrophages internalize collagen in a mannose receptor-dependent process. Activated macrophages were isolated from the peritoneum of either MR-/- mice or littermate wildtype (MR+/+) mice 72 hours after thioglycollate injection. The internalization of collagen was measured for MR+/+ (column 1 and 2) and MR-/- macrophages (column 3 and 4) in the absence (columns 1 and 3) or presence (columns 2 and 4) of 10 µg/ml of mAb 5f4. Internalization by MR+/+ macrophages in the absence of antibody was defined as 100% internalization. F, Positive control for mannose receptor-mediated endocytosis. Murine MR+/+ and littermate MR-/- macrophages were assayed for their ability to internalize radiolabeled mannose-BSA. For A-F, all samples were analyzed in triplicates. Error bars indicate standard deviations.

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

17

Table 1

Species Origin Reference Epithelial cell lines LNCaP human prostate carcinoma (72) MDA-MB-231 human breast adenocarcinoma (73) CaCo-2 human colorectal adenocarcinoma (74) HeLa human cervix carcinoma (75) MCF-7 human breast adenocarcinoma (76) HEK-293 human embryonic kidney (77) Lewis Lung Carcinoma (LLC) murine lung carcinoma (78) B16F10 murine skin melanoma (79)

Mesenchymal cell lines HGF-1 human healthy gingiva (80) MG63 human osteosarcoma (81) MRC-5 human lung fibroblast (82) HT1080 human fibrosarcoma (83) RD human rhabdomyosarcoma (84) NCTC 2472 murine sarcoma (85) NIH/3T3 murine embryonic fibroblast (86)

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

B)A)Collagen I

internalization

uPARAP+/

+0

20

40

60

80

100

120Holo-transferrininternalization

Collagen I internalization by murine fibroblasts

D)

C)

Collagen I internalization by human sarcoma cells

E)

% o

f re

fere

nce c

ells

uPARAP+/

+

+ m

Ab 5

f4

uPARAP-/-

uPARAP-/-

+ m

Ab 5

f4

uPARAP+/

+

uPARAP+/

+

+ m

Ab 5

f4

0

20

40

60

80

100

% o

f re

fere

nce c

ells

0.0

1

0.0

3

0.1

0.3 1 3

10

30

100-

U-/

- fi

bro

bla

sts

10

0

ug

/ml

co

ntr

ol m

AbmAb 5f4

( g/ml)µ 0.0

1

0.0

3

0.1

0.3 1 3

10

30

100-

10

0

g/m

lco

ntr

ol m

Ab

µ

Fig.1

250

150

100

75

50

37

2520

Mr

uPAR

AP+/+

uPAR

AP-/-

uPAR

AP+/+

hear

t

uPAR

AP-/- h

eart

uPAR

AP+/+

lung

uPAR

AP-/- lu

ng

fibroblasts tissue

18

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

Fig.2

+ 10 µg/ml 5f4

Internalization of fluorescent-labeled collagen IV

+

E6

4d

C D

uP

AR

AP

+/+

fib

rob

last

sM

G6

3

no Ab

E F

Internalization of fluorescent-labeled gelatin

BA

no mAb

0.01

ug/m

l 5f4

0.1

ug/ml 5

f4

1 ug/m

l 5f4

10 u

g/ml 5

f4

100

ug/ml 5

f4

uPARAP -/

-

% o

f u

ntr

eate

d f

ibro

bla

sts

0

20

40

60

80

100

120

G Internalization of radio-labeled collagen IV

19

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

Fig.3

20

Fibroblasts

MG63

Control mAbmAb 5f4

Control mAbmAb 5f4

uPARAP

Loadingcontrol

uPARAP

Loadingcontrol

A B

C

uPARAP level

% o

f an

ti-T

NP

tre

ate

d c

ells

0

20

40

60

80

100

120

ControlmAb

MG63

mAb 5f4

Fibroblasts

uPARAP level

% o

f an

ti-T

NP

tre

ate

d c

ells

0

20

40

60

80

100

120

ControlmAb

mAb 5f4

D

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

250

150

100

75

50

37

2520

kDa

15

3/4 fragment

1/4 fragment

Intact -chainsα

1: In

tact collage

n I

2: C

leav

ed collage

n I

3: u

PARAP +

/+ fibr

oblasts

4: u

PARAP -/

- fibro

blas

ts

5: u

PARAP +

/+ fibr

oblasts +

50 µ

g/m

l 5f4

B)

A)

Fig.4

21

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

uPARAP level (% of reference cells)

0 20 40 60 80 100 120 140 160

Co

lla

ge

n i

nte

rna

liza

tio

n

(% o

f re

fere

nc

e c

ell

s)

0

20

40

60

80

100

120

140

A)

B)

uPARAP level(% of reference cells)

0 20 40 60 80 100 120 140 160 180

0

100

200

300

400

500

600

(% o

f re

fere

nc

e c

ell

s)

Ho

lo-t

ran

sfe

rin

in

tern

ali

zati

on

Fig.5

22

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

Collagen I internalization

% o

f re

fere

nce c

ell

s

uPARAP level

0

20

40

60

80

100

120

140

no antibodymAb 5f4

uPARAP+/

+ fib

robla

sts

HGF-1

MRC-5

MG63

NCTC

247

2

NIH

/3T3

HT10

80HeL

aLLC

MDA-M

B-2

31

RD c

ells

B16

F10

HEK

-293

MCF-7

LNCaP

CaC

o-2

uPARAP-/-

fibro

blast

s

Fig.6

23

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

Collagen I internalization

0

20

40

60

80

100

120

140

160

180

uPARAP level

0

50

100

150

200

Holo-transferrininternalization

0

20

40

60

80

100

A) B) C)

D) Collagen I internalization

% o

f re

fere

nce c

ells

0

20

40

60

80

100

120

% o

f re

fere

nce c

ell

s

% o

f re

fere

nce c

ell

s

% o

f re

fere

nce c

ell

s

GD 2

5

GD 2

5

GD 2

5

Gd25

+ 5

f4

GD25

-bet

a

GD25

-bet

a

GD25

-bet

a

GD25

-bet

a +

5f4

MG63

MG63

+ 1

0 µg

/ml 5

f4

MG63

+ 2

µg/m

l 4B4

MG63

+ 1

0 µg

/ml 4

B4

MG63

+ 5

0 µM

RGD

MG63

+ 2

00 µ

M R

GD

Fig.7

24

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from

Mannose-BSA internalization

0

20

40

60

80

100

120

140

Collagen I internalization

0

20

40

60

80

100

120

140

160

uPARAP level

% o

f re

fere

nce

ce

lls

0

20

40

60

80

100

120

A) B) C)

D) E) F)

% o

f re

fere

nce

ce

lls

MR+/

+

MR-/-

Collagen I internalization

MR+/

+% o

f u

ntr

eate

d M

R+

/+ m

acro

ph

ag

es

0

20

40

60

80

100

120

MR-/-

MR+/

+

+mAb 5

f4

MR-/-

+mAb 5

f4

% o

f u

ntr

eate

d M

R+

/+ m

acro

ph

ag

es

MG63

MG63

MG63

+mAb 5

f4

Mac

rophag

es

Mac

rophag

es

Collagen I internalization

0

100

200

300

400

500

% o

f u

ntr

ea

ted

ma

cro

ph

ag

es

Mac

rophag

es

Mac

rophag

es

+E64

d

Mac

rophag

es

+mAb 5

f4

Fig.8

Collagen I internalization

mac

rophag

es

mac

rophag

es +

4B4

mac

rophag

es +

RGD

0

20

40

60

80

100

120

140

% o

f u

ntr

eate

d m

acro

ph

ag

es

25

by guest on Decem

ber 5, 2013http://w

ww

.jbc.org/D

ownloaded from